TAK-071 Scopolamine-Induced Cognitive Impairment Study (Q66080121)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | TAK-071 Scopolamine-Induced Cognitive Impairment Study |
clinical trial |
Statements
A Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, 5-Period Crossover, Phase 1b Study To Evaluate The Effects Of Single Oral Administration of TAK-071 On Scopolamine-Induced Cognitive Impairment In Healthy Subjects (English)
0 references
21 November 2016
0 references
2 August 2017
0 references
18
0 references
18 year
0 references
55 year
0 references